The global generic oncology sterile injectables market by Product Type (Chemotherapy (Alkylating Agents, Antimetabolites, Plant Alkaloids, Antitumor Antibiotics, and Others) Monoclonal Antibodies, Cytokines, and Peptide Hormones), by Disease Indication (Ovarian Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 9,838.0 million in 2017 and is projected to exhibit a CAGR of 11.4% over the forecast period (2018–2026), as highlighted in a new report published by Coherent Market Insights. Availability of wide number of products for treatment of cancer, and ongoing research and development of different therapies is expected to fuel growth of the generic oncology sterile injectable market.
Teva Pharmaceutical Industries is focusing on generic pipeline that includes 330 product applications awaiting FDA approval in the U.S., including 71 tentative approvals till December 31, 2016. Pfizer in December 2016, entered into strategic collaboration with IGNITE Immunotherapy Inc. for discovery and development of targeted and next-generation intravenous oncolytic vaccines for cancer immunotherapy. According to Generics and Biosimilars Initiative, 2017, around 15 biosimilars of bevacizumab are in development. Moreover, Sandoz has leading biosimilar pipeline and plans to launch five biosimilar to treat oncology and immunology biologics by 2020. Baxter International, in 2017, entered into strategic partnership with ScinoPharm Taiwan Ltd. to develop, manufacture, and commercialize five injectables used in oncology treatments.
Browse 28 Market Data Tables and 25 Figures spread through 201 Pages and in-depth TOC on Generic Oncology Sterile Injectable Market by Product Type (Chemotherapy (Alkylating Agents, Antimetabolites, Plant Alkaloids, Antitumor Antibiotics, and Others) Monoclonal Antibodies, Cytokines, and Peptide Hormones), by Disease Indication (Ovarian Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and, Africa) - Global Forecast to 2025
To know the latest trends and insights prevalent in the generic oncology sterile injectables market, click the link below:
Key players in the market are focusing on strategic acquisitions, in order to enhance their market share. Pfizer, in 2014, acquired InnoPharma, which enabled them to acquire InnoPharma’s 10 U.S. FDA approved generic products and 19 pipeline and over 30 injectable products in development phase, which includes products for cancer and central nervous disorders. Pfizer, in 2016, acquired Medivation Inc. – a biopharmaceutical company focused on developing and commercializing small molecules for oncology. Furthermore, Pfizer, Inc. acquired Hospira sterile injectables pharmaceuticals in 2015. Teva acquired the Allergan plc’s worldwide generic pharmaceuticals business (Actavis Generics) in 2016. Moreover, in 2016, Mylan completed acquisition of topical-focused business (both generic and specialty products) from Renaissance Acquisition Holdings, a contract manufacturing company. In 2015, Hikma Pharmaceuticals PLC acquired EIMC United Pharmaceuticals (EUP), a pharmaceutical manufacturing company specializing in oncology products.
Key Takeaways of the Generic Oncology Sterile Injectables Market:
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
Email: [email protected]
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.